Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies
Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with LivinitiTM, an innovative Pharmacy Benefit Manager, to improve the management of moderate-to-severe psoriasis patients. This pilot program will utilize Mind.Px to improve clinical outcomes while reducing biologic drug costs for self-funded employers.
In the United States, psoriasis affects more than three percent of the population. Moderate-to-severe disease severity accounts for approximately one-third of psoriasis diagnoses.ii This auto-immune condition often leads to absenteeism or major problems at work, depression, and other clinical comorbidities.ii Specialty drug spending for psoriasis is escalating…